| Colette D Lieber, MD | |
|
400 Franklin Tpk, Suite 208, Mahwah, NJ 07430 | |
| (201) 825-0009 | |
| (201) 825-2622 |
| Full Name | Colette D Lieber |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 42 Years |
| Location | 400 Franklin Tpk, Mahwah, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396844163 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 51951 (New Jersey) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Clark Dermatology Llc | 5395703573 | 43 |
News Archive
Myeloproliferative neoplasms (MPN) comprise a family of blood cancers characterized by clonal expansion of a single blood cell type. Untreated, these cancers can progress to bone marrow failure and acute myeloid leukemia. Several groups have identified activating mutations in the JAK2 gene as associated with MPN; JAK2 inhibition has therefore emerged as approach to MPN therapy.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Indomethacin for Injection. Indomethacin is therapeutically equivalent to the reference-listed drug INDOCIN® I.V., by Lundbeck, Inc.
The Office of Health Economics today released the third edition of its popular primer, Health Economics: An Introduction to Economic Evaluation, authored by Gisela Kobelt who has extensive hands-on experience in the field. What distinguishes this book from other such reviews are its fifteen concrete "study examples," which focus on pharmaceuticals.
A protein that shields tumor cells from cell death and exerts resistance to chemotherapy has an Achilles heel, a vulnerability that can be exploited to target and kill the very tumor cells it usually protects, researchers from the University of Illinois at Chicago show in a new study published in the Dec. 9 issue of Cancer Cell.
› Verified 4 days ago
| Entity Name | Clark Dermatology Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851562425 PECOS PAC ID: 5395703573 Enrollment ID: O20080920000007 |
News Archive
Myeloproliferative neoplasms (MPN) comprise a family of blood cancers characterized by clonal expansion of a single blood cell type. Untreated, these cancers can progress to bone marrow failure and acute myeloid leukemia. Several groups have identified activating mutations in the JAK2 gene as associated with MPN; JAK2 inhibition has therefore emerged as approach to MPN therapy.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Indomethacin for Injection. Indomethacin is therapeutically equivalent to the reference-listed drug INDOCIN® I.V., by Lundbeck, Inc.
The Office of Health Economics today released the third edition of its popular primer, Health Economics: An Introduction to Economic Evaluation, authored by Gisela Kobelt who has extensive hands-on experience in the field. What distinguishes this book from other such reviews are its fifteen concrete "study examples," which focus on pharmaceuticals.
A protein that shields tumor cells from cell death and exerts resistance to chemotherapy has an Achilles heel, a vulnerability that can be exploited to target and kill the very tumor cells it usually protects, researchers from the University of Illinois at Chicago show in a new study published in the Dec. 9 issue of Cancer Cell.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Colette D Lieber, MD 400 Franklin Turnpike, Suite 208, Mahwah, NJ 07430 Ph: (201) 825-0009 | Colette D Lieber, MD 400 Franklin Tpk, Suite 208, Mahwah, NJ 07430 Ph: (201) 825-0009 |
News Archive
Myeloproliferative neoplasms (MPN) comprise a family of blood cancers characterized by clonal expansion of a single blood cell type. Untreated, these cancers can progress to bone marrow failure and acute myeloid leukemia. Several groups have identified activating mutations in the JAK2 gene as associated with MPN; JAK2 inhibition has therefore emerged as approach to MPN therapy.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Indomethacin for Injection. Indomethacin is therapeutically equivalent to the reference-listed drug INDOCIN® I.V., by Lundbeck, Inc.
The Office of Health Economics today released the third edition of its popular primer, Health Economics: An Introduction to Economic Evaluation, authored by Gisela Kobelt who has extensive hands-on experience in the field. What distinguishes this book from other such reviews are its fifteen concrete "study examples," which focus on pharmaceuticals.
A protein that shields tumor cells from cell death and exerts resistance to chemotherapy has an Achilles heel, a vulnerability that can be exploited to target and kill the very tumor cells it usually protects, researchers from the University of Illinois at Chicago show in a new study published in the Dec. 9 issue of Cancer Cell.
› Verified 4 days ago